Diagnostic Evaluation of Non-Interpretable Results Associated with rpoB Gene in Genotype MTBDRplus Ver 2.0 |
Singh, Binit Kumar
(Department of Medicine, All India Institute of Medical Sciences)
Sharma, Rohini (Department of Medicine, All India Institute of Medical Sciences) Kodan, Parul (Department of Medicine, All India Institute of Medical Sciences) Soneja, Manish (Department of Medicine, All India Institute of Medical Sciences) Jorwal, Pankaj (Department of Medicine, All India Institute of Medical Sciences) Nischal, Neeraj (Department of Medicine, All India Institute of Medical Sciences) Biswas, Ashutosh (Department of Medicine, All India Institute of Medical Sciences) Sarin, Sanjay (Foundation for Innovative New Diagnostics (FIND)) Ramachandran, Ranjani (World Health Organization) Wig, Naveet (Department of Medicine, All India Institute of Medical Sciences) |
1 | World Health Organization. Global tuberculosis report 2019 [Internet]. Geneva: World Health Organization; 2019 [cited 2020 Mar 2]. Available from: http://www.who.int/tb/publications/global_report/en/. |
2 | Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J 2017;49:1601075. DOI |
3 | World Health Organization. WHO policy statement: molecular line-probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. Geneva: World Health Organization; 2008. |
4 | GenoType MTBDRplus, ver 2.0. Instructions for use [Internet]. Nehren: Hain LifeScience GmbH; 2013 [cited 2018 Nov 30]. Available from: https://www.ghdonline.org/uploads/MTBDRplusV2_0212_304A-02-02.pdf. |
5 | World Health Organization. The use of molecular line-probe assay for the detection of resistance to isoniazid and rifampicin: policy update. WHO/HTM/TB/2016.12 [Internet]. Geneva: World Health Organization; 2016 [cited 2020 Mar 2]. Available from: http://apps.who.int/iris/bitstream/handle/10665/250586/9789241511261-eng.pdf?sequence=1&isAllowed=y. |
6 | World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational 'how to' practical considerations [Internet]. Geneva: World Health Organization; 2011 [cited 2012 Jan 13]. Available from: http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf. |
7 | Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012;50:3712-6. DOI |
8 | Van Deun A, Aung KJ, Hossain A, de Rijk P, Gumusboga M, Rigouts L, et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 2015;19:185-90. DOI |
9 | Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, et al. MTBDRplus and MTBDRsl assays: absence of wild-type probe hybridization and implications for detection of drug-resistant tuberculosis. J Clin Microbiol 2016;54:912-8. DOI |
10 | Jo KW, Lee S, Kang MR, Sung H, Kim MN, Shim TS. Frequency and type of disputed rpoB mutations in Mycobacterium tuberculosis isolates from South Korea. Tuberc Respir Dis 2017;80:270-6. DOI |
11 | Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger M, et al. Characterization of rifampinresistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994;38:2380-6. DOI |
12 | World Health Organization. Global tuberculosis report 2013. Geneva: World Health Organization; 2013. |
13 | Sharma SK, Chaubey J, Singh BK, Sharma R, Mittal A, Sharma A. Drug resistance patterns among extra-pulmonary tuberculosis cases in a tertiary care centre in North India. Int J Tuberc Lung Dis 2017;21:1112-7. DOI |
14 | Hofmann-Thiel S, Hoffmann H, Hillemann D, Rigouts L, Van Deun A, Kranzer K. How should discordance between molecular and growth-based assays for rifampicin resistance be investigated? Int J Tuberc Lung Dis 2017;21:721-6. DOI |
15 | Paramasivan CN, Raizada N. Line probe assay: a look at noninterpretable results. Int J Tuberc Lung Dis 2016;20:146. DOI |
16 | Yadav RN, Singh BK, Sharma SK, Sharma R, Soneja M, Sreenivas V, et al. Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India. PLoS One 2013;8:e72036. DOI |
17 | Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis. J Clin Microbiol 2014;52:1846-52. DOI |
18 | Singh BK, Sharma SK, Sharma R, Sreenivas V, Myneedu VP, Kohli M, et al. Diagnostic utility of a line probe assay for multidrug resistant-TB in smear-negative pulmonary tuberculosis. PLoS One 2017;12:e0182988. DOI |
19 | Andres S, Hillemann D, Rusch-Gerdes S, Richter E. Occurrence of rpoB mutations in isoniazid-resistant but rifampinsusceptible Mycobacterium tuberculosis isolates from Germany. Antimicrob Agents Chemother 2014;58:590-2. DOI |
20 | Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013;51:2633-40. DOI |
21 | Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009;47:3501-6. DOI |
22 | Mani C, Selvakumar N, Narayanan S, Narayanan PR. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol 2001;39:2987-90. DOI |
23 | Nikam C, Patel R, Sadani M, Ajbani K, Kazi M, Soman R, et al. Redefining MTBDRplus test results: what do indeterminate results actually mean? Int J Tuberc Lung Dis 2016;20:154-9. DOI |